Current Report Filing (8-k)
August 09 2022 - 4:18PM
Edgar (US Regulatory)
0001360214
false
0001360214
2022-08-09
2022-08-09
0001360214
HROW:CommonStock0.001ParValuePerShareMember
2022-08-09
2022-08-09
0001360214
HROW:Sec8.625SeniorNotesDue2026Member
2022-08-09
2022-08-09
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): August 9, 2022
HARROW
HEALTH, INC.
(Exact
name of registrant as specified in its charter)
Delaware |
|
001-35814 |
|
45-0567010 |
(State
or other jurisdiction
of
incorporation) |
|
(Commission
File Number) |
|
(IRS Employer
Identification No.) |
102
Woodmont Blvd., Suite 610 |
|
|
Nashville,
Tennessee |
|
37205 |
(Address
of principal executive offices) |
|
(Zip
Code) |
Registrant’s
telephone number, including area code: (615) 733-4730
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
Symbol(s) |
|
Name
on exchange on which registered |
Common
Stock, $0.001 par value per share |
|
HROW |
|
The
NASDAQ Global Market |
8.625%
Senior Notes due 2026 |
|
HROWL |
|
The
NASDAQ Global Market |
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2
of the Securities Act of 1934: Emerging growth company ☐
If
any emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
2.02 Results of Operations and Financial Condition.
On
August 9, 2022, Harrow Health, Inc. (the “Company”) issued a press release and a letter to stockholders announcing its financial
results for the period ended June 30, 2022 and an update on recent corporate events. The press release and letter to stockholders are
being furnished as Exhibits 99.1 and 99.2, respectively, to this Current Report on Form 8-K.
Item
7.01. Regulation FD Disclosure
Attached
as Exhibit 99.3 to this Current Report on Form 8-K is a presentation of the Company that may be used by the management of the
Company at investor conferences and at meetings describing the Company.
The
information furnished under Items 2.02 and 7.01 of this Current Report on Form 8-K, including Exhibits 99.1, 99.2 and 99.3,
shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the
“Exchange Act”), or otherwise subject to the liabilities of that Section. The information in Items 2.02 and 7.01, including
Exhibits 99.1, 99.2 and 99.3, shall not be deemed incorporated by reference into any filing under the Securities
Act of 1933, as amended, or the Exchange Act, except to the extent it is specifically incorporated by reference but regardless of any
general incorporation language in such filing.
The
information furnished under Items 2.02 and 7.01 of this Current Report on Form 8-K, including Exhibits 99.1, 99.2 and 99.3,
shall not be deemed to constitute an admission that such information or exhibit is required to be furnished pursuant to Regulation FD
or that such information or exhibit contains material information that is not otherwise publicly available. In addition, the Company
does not assume any obligation to update such information or exhibit in the future.
Item
9.01. Financial Statements and Exhibits
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
HARROW
HEALTH, INC. |
|
|
Dated:
August 9, 2022 |
By: |
/s/
Andrew R. Boll |
|
Name: |
Andrew
R. Boll |
|
Title: |
Chief
Financial Officer |
Harrow (NASDAQ:HROW)
Historical Stock Chart
From Mar 2024 to Apr 2024
Harrow (NASDAQ:HROW)
Historical Stock Chart
From Apr 2023 to Apr 2024